Cockroach-induced IL9, IL13, and IL31 expression and the development of allergic asthma in urban children. / National Institute of Allergy and Infectious Diseases-Sponsored Inner-City Asthma Consortium.In: Journal of Allergy and Clinical Immunology, 2021.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Cockroach-induced IL9, IL13, and IL31 expression and the development of allergic asthma in urban children
AU - National Institute of Allergy and Infectious Diseases-Sponsored Inner-City Asthma Consortium
AU - LeBeau, Petra
AU - Lockhart, Alexandre
AU - Togias, Alkis
AU - Sandel, Megan T.
AU - Gereige, Jessica D.
AU - Bacharier, Leonard
AU - Lovinsky-Desir, Stephanie
AU - Wood, Robert A.
AU - James, Robert
AU - Busse, William W.
AU - Gern, James E.
AU - Altman, Matthew C.
N1 - Funding Information: Supported with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (under contract numbers NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, and UM2AI117870), as well as with additional support was provided by the National Center for Research Resources, National Institutes of Health (under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, UL1TR000040, UL1TR001079, and 5UL1RR024992-02). All of the authors, with the exception of A.T., J.D.G., and M.C.A., report grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases/Division of Allergy, Immunology, and Transplantation during the conduct of the study. Disclosure of potential conflict of interest: L. Bacharier reports personal fees from GlaxoSmithKline, Genentech/Novartis, DBV Technologies, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, and Circassia, as well as personal fees and nonfinancial support from Merck, Teva, and Boehringer Ingelheim outside the submitted work. J. E. Gern reports consulting fees from Regeneron, consulting fees and stock options from Meissa Vaccines, Inc, and consulting fees from AstraZeneca; personal fees from PREP Biopharm, Inc, MedImmune, and Ena Pharmaceuticals; and a pending patent for methods of propagating rhinovirus C in previously unsusceptible cell lines and adapted rhinovirus C outside the submitted work. J. D. Gereige reports grants from the National Institutes of Health (T32) outside the submitted work. W. W. Busse reports personal fees from Boston Scientific, Novartis, GlaxoSmithKline, Genentech, Sanofi/Genzyme, AstraZeneca, Teva, Regeneron, and Elsevier outside the submitted work. R. A. Wood reports grants from DNV, Aimmune, Astellas, HAL-Allergy, and Regeneron and royalties outside the submitted work. M. C. Altman reports personal fees from Sanofi-Regeneron outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
UR - http://www.scopus.com/inward/record.url?scp=85102244016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102244016&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2021.01.022
DO - 10.1016/j.jaci.2021.01.022
M3 - Article
C2 - 33712279
AN - SCOPUS:85102244016
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749